Free lookups: 2/3 Unlock Pro
Clinical reference Find a medicine
Ctrl K
2 of 3 free lookups remaining Upgrade
New search Medicine profile Triprolidine/Guaifenesin

Clinical medicine profile

Triprolidine/Guaifenesin

Therapeutic agent (verify pharmacological class)

POM
Evidence state General guidance Reviewed 14 Aug 2026
Route
See product SmPC
Schedule
POM
ATC
Not assigned
PPB status
registered
Patient advice Check interactions
Verification required

This profile needs source confirmation

Some sections contain general class guidance rather than medicine-specific evidence. Confirm prescribing decisions against the current SmPC and Kenya STG/EML.

01 Risk first

Safety essentials

The information most likely to change a prescribing or dispensing decision.

Contraindications

  • [From component Guaifenesin BP 50mg, Bromhexine Hydrochloride BP 2mg, Salbutamol Sulphate BP 1mg/5mL] Concomitant use with beta-blockers, pregnancy, MAOI, serious cardiac or thyroid diseases.

Precautions

  • Warnings Liver warning This product contains acetaminophen.
  • Severe liver damage may occur if you take: more than 4000 mg in 24 hours, which is the maximum daily amount with other drugs containing acetaminophen 3 or more alcoholic drinks daily while using this product Allergy alert Acetaminophen may cause severe skin reactions.
  • Symptoms may include: skin reddening blisters rash If a skin reaction occurs, stop use and seek medical help right away.
  • Sore throat warning If sore throat is severe, persists for more than 2 days, is accompanied or followed by fever, headache, rash, nausea, or vomiting, consult a doctor promptly.
  • Do not use with any other drug containing acetaminophen (prescription or nonprescription).
  • If you are not sure whether a drug contains acetaminophen, ask a doctor or pharmacist. if you are now taking a prescription monoamine oxidase inhibitor (MAOI) (certain drugs for depression, psychiatric, or emotional conditions, or Parkinson's disease), or for 2 weeks after stopping the MAOI drug.
  • If you do not know if your prescription drug contains an MAOI, ask a doctor or pharmacist before taking this product.
  • Ask a doctor before use if you have liver disease glaucoma trouble urinating due to an enlarged prostate gland a breathing problem such as emphysema or chronic bronchitis persistent or chronic cough such as occurs with smoking, asthma, or emphysema cough that occurs with too much phlegm (mucus) Ask a doctor or pharmacist before use if you are taking the blood thinning drug warfarin taking sedatives or tranquilizers When using this product do not use more than directed excitability may occur, especially in children marked drowsiness may occur alcohol, sedatives, and tranquilizers may increase drowsiness avoid alcoholic drinks use caution when driving a motor vehicle or operating machinery Stop use and ask a doctor if pain or cough gets worse or lasts more than 7 days fever gets worse or lasts more than 3 days redness or swelling is present new symptoms occur cough comes back, or occurs with fever, rash, or headache that lasts.
  • These could be signs of a serious condition.
  • If pregnant or breast-feeding, ask a health professional before use.
  • Keep out of reach of children.
  • Overdose warning Taking more than the recommended dose (overdose) may cause liver damage.
02 Point of care

Dosing matrix

Population and organ-function guidance, shown together for faster comparison.

Adult

Directions do not take more than directed (see Overdose warning ) do not take more than 4 doses in any 24-hour period measure only with dosing cup provided do not use dosing cup with other products dose as follows or as directed by a doctor adults and children 12 years of age and older: 20 mL in dosing cup provided every 4 hours children under 12 years of age: do not use

Paediatric

See label paediatric section if present; otherwise use paediatric formulary — do not extrapolate adult doses.

Renal

Review renal impairment dosing; many agents need CrCl/eGFR adjustment.

  • CrCl 0–120: Confirm renal dosing in product SmPC / primary label.
Hepatic

Review hepatic impairment dosing; monitor LFTs if agent is hepatically cleared or hepatotoxic.

03 Clinical use

Use, effects & interactions

Indications

Uses temporarily relieves these common cold and flu symptoms: cough minor aches and pains sore throat headache runny nose sneezing itching of the nose or throat itchy, watery eyes due to hay fever temporarily reduces fever controls cough to help you get to sleep

Adverse effects

  • [From component Guaifenesin BP 50mg, Bromhexine Hydrochloride BP 2mg, Salbutamol Sulphate BP 1mg/5mL] Muscle cramps, tachycardia, palpitation, fine muscle tremor, headache, peripheral vasodilation, allergic reactions, insomnia, dizziness.
  • Fixed-dose/multi-ingredient product.
  • Clinical details partially inherited from component monographs: Guaifenesin BP 50mg, Bromhexine Hydrochloride BP 2mg, Salbutamol Sulphate BP 1mg/5mL.
  • Confirm combination SmPC for exact dosing.
04 Pharmacology

Mechanism & disposition

Mechanism is agent-specific.

Mechanism is agent-specific.At receptor, enzyme, ion channel, transpor…Confirm precise molecular mechanism in cur…
Read complete mechanism

Mechanism is agent-specific. At receptor, enzyme, ion channel, transporter or microbial target level, the drug alters a physiological or pathological pathway to produce its therapeutic effect. Confirm precise molecular mechanism in current SmPC / pharmacology reference for this INN before high-stakes decisions.

Onset

Product-specific

Duration

Product-specific

Route

See product SmPC

Elimination

are product-specific. Consider food effects, protein binding, hepatic CYP/UGT

Half-life

when adjusting for organ impairment, age and drug interactions. Verify parameters in the current SmPC.

05 Special populations

Pregnancy, lactation & diet

Pregnancy

[From component Guaifenesin BP 50mg, Bromhexine Hydrochloride BP 2mg, Salbutamol Sulphate BP 1mg/5mL] See FDA/DailyMed label section on pregnancy; use only if potential benefit justifies potential risk.

Lactation

[Triprolidine] Assess infant risk vs benefit of maternal therapy; prefer agents with lactation data. [Guaifenesin] Assess infant risk vs benefit of maternal therapy; prefer agents with lactation data.

06 Kenya market

Brands & loaded prices

From
Median
Listings0
BrandManufacturerPackObserved price
No reviewed brand listings are linked yet.
07 Provenance

Sources & review state

Primary sourceLocal active-ingredient clinical extract; FDA drug label via OpenFDA/DailyMed; Component monographs (multi-source pipeline); Professional class pharmacology (Therapeutic agent (verify pharmacological class))
Last reviewed14 Aug 2026
EvidenceGeneral guidance
Open source document ↗

Decision support only. Confirm patient-specific decisions against the current product SmPC, Kenya STG/EML, and professional judgement.